Pelz, Patricia http://orcid.org/0000-0001-7494-546X
Genauck, Alexander
Lorenz, Robert C.
Wüstenberg, Torsten
Wackerhagen, Carolin
Charlet, Katrin
Gleich, Tobias
Geisel, Olga
Heinz, Andreas
Müller, Christian A.
Beck, Anne
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 257, DFG: Project-ID 402170461 – TRR 265)
Charité - Universitätsmedizin Berlin
Article History
Received: 11 March 2022
Accepted: 5 December 2022
First Online: 20 December 2022
Declarations
:
: This substudy is subordinate by the main (BACLAD-) study, which has been a preregistered, randomized, double-blind, placebo-controlled pharmacological trial (clinical.gov: NCT01266655; published in Müller et al.CitationRef removed), which have been approved by the Ethics Committee of the Charité – Universitätsmedizin Berlin and the Federal Institute for Drugs and Medical Devices (BfArM) and was conducted in accordance with the latest version of the Declaration of Helsinki. All patients gave written fully informed consent for participation and included in this fMRI substudy after randomization for the main trial.
: The authors declare no competing interests.